Effect of ginkgo diterpene lactone meglumine on the quality of life in patients with acute ischemic stroke.

IF 3.2 2区医学 Q1 HEALTH CARE SCIENCES & SERVICES

Health and Quality of Life Outcomes Pub Date : 2024-11-15 DOI:10.1186/s12955-024-02315-1

Xue Tian, Qin Xu, Xue Xia, Yijun Zhang, Xingquan Zhao, Anxin Wang

{"title":"Effect of ginkgo diterpene lactone meglumine on the quality of life in patients with acute ischemic stroke.","authors":"Xue Tian, Qin Xu, Xue Xia, Yijun Zhang, Xingquan Zhao, Anxin Wang","doi":"10.1186/s12955-024-02315-1","DOIUrl":null,"url":null,"abstract":"Objective: Ginkgo diterpene lactone meglumine (GDLM) could improve the functional outcome after acute ischemic stroke (AIS). This study aimed to investigate the efficacy of GDLM on the quality of life in patients with AIS in China.Methods: This is a post hoc analysis of Efficacy and Safety of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke trial. The quality of life was measured using the EuroQoL questionnaire, including EQ-5D and EQ visual analogue scale (EQ-VAS). The primary outcomes were changes in EQ-5D and EQ-VAS from baseline to day 14 and day 90 after randomization.Results: A total of 3219 patients with completed data on outcomes were enrolled, with median age of 63 years (interquartile range, 55-70) and 2,067 (64.2%) men. GDLM was associated with a significant decrease in scores of ED-5Q components (from 0 [no problem] to 3[extreme problem]), the mean difference between GDLM and placebo group was -0.14 for mobility, -0.11 for usual activities and self-care, -0.09 for pain/discomfort, and -0.34 for anxiety/depression on day 14, respectively. Similar results were observed on day 90. Additionally, there was statistically significant difference of changes in EQ-VAS between the GDLM group and the placebo group from baseline to day 14 (mean difference, 1.70; 95% confidence interval [CI], 0.78-2.62; P = 0.0003) and to day 90 after randomization (mean difference, 3.29; 95% CI, 2.37-4.22; P < 0.001).Conclusions: In this analysis of Chinese patients with AIS, GDLM could improve the 14-day and 90-day quality of life compared with the placebo.Trial registration: URL: https://www.Clinicaltrials: gov . Unique identifier: NCT02526225. Registration Date: 2016-02-01.","PeriodicalId":12980,"journal":{"name":"Health and Quality of Life Outcomes","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health and Quality of Life Outcomes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12955-024-02315-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Ginkgo diterpene lactone meglumine (GDLM) could improve the functional outcome after acute ischemic stroke (AIS). This study aimed to investigate the efficacy of GDLM on the quality of life in patients with AIS in China.

Methods: This is a post hoc analysis of Efficacy and Safety of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke trial. The quality of life was measured using the EuroQoL questionnaire, including EQ-5D and EQ visual analogue scale (EQ-VAS). The primary outcomes were changes in EQ-5D and EQ-VAS from baseline to day 14 and day 90 after randomization.

Results: A total of 3219 patients with completed data on outcomes were enrolled, with median age of 63 years (interquartile range, 55-70) and 2,067 (64.2%) men. GDLM was associated with a significant decrease in scores of ED-5Q components (from 0 [no problem] to 3[extreme problem]), the mean difference between GDLM and placebo group was -0.14 for mobility, -0.11 for usual activities and self-care, -0.09 for pain/discomfort, and -0.34 for anxiety/depression on day 14, respectively. Similar results were observed on day 90. Additionally, there was statistically significant difference of changes in EQ-VAS between the GDLM group and the placebo group from baseline to day 14 (mean difference, 1.70; 95% confidence interval [CI], 0.78-2.62; P = 0.0003) and to day 90 after randomization (mean difference, 3.29; 95% CI, 2.37-4.22; P < 0.001).

Conclusions: In this analysis of Chinese patients with AIS, GDLM could improve the 14-day and 90-day quality of life compared with the placebo.

Trial registration: URL: https://www.

Clinicaltrials: gov . Unique identifier: NCT02526225. Registration Date: 2016-02-01.

查看原文本刊更多论文

银杏二萜内酯葡甲胺对急性缺血性中风患者生活质量的影响。

目的：银杏二萜内酯葡甲胺（GDLM银杏二萜内酯葡甲胺（GDLM）可改善急性缺血性脑卒中（AIS）后的功能预后。本研究旨在探讨银杏二萜内酯葡甲胺对中国 AIS 患者生活质量的影响：本研究是银杏二萜内酯美格列净对急性缺血性脑卒中疗效和安全性试验的事后分析。生活质量采用欧洲生活质量调查问卷进行测量，包括EQ-5D和EQ视觉模拟量表（EQ-VAS）。主要结果是随机化后从基线到第14天和第90天EQ-5D和EQ-VAS的变化：共有 3219 名患者获得了完整的结果数据，中位年龄为 63 岁（四分位间范围为 55-70），男性患者为 2067 人（64.2%）。第 14 天，GDLM 与安慰剂组之间的平均差异分别为：行动能力-0.14，日常活动和自我护理-0.11，疼痛/不适-0.09，焦虑/抑郁-0.34。第 90 天也观察到了类似的结果。此外，GDLM 组和安慰剂组的 EQ-VAS 从基线到随机化后第 14 天（平均差异为 1.70；95% 置信区间 [CI]，0.78-2.62；P = 0.0003）和第 90 天（平均差异为 3.29；95% 置信区间 [CI]，2.37-4.22；P 结论：GDLM 组和安慰剂组的 EQ-VAS 变化有显著统计学差异：在这项对中国 AIS 患者的分析中，与安慰剂相比，GDLM 可改善 14 天和 90 天的生活质量：URL: https://www.Clinicaltrials: gov .唯一标识符：NCT02526225.注册日期：2016-02-01.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Health and Quality of Life Outcomes 医学-卫生保健

CiteScore

7.30

自引率

2.80%

发文量

154

审稿时长

3-8 weeks

期刊介绍： Health and Quality of Life Outcomes is an open access, peer-reviewed, journal offering high quality articles, rapid publication and wide diffusion in the public domain. Health and Quality of Life Outcomes considers original manuscripts on the Health-Related Quality of Life (HRQOL) assessment for evaluation of medical and psychosocial interventions. It also considers approaches and studies on psychometric properties of HRQOL and patient reported outcome measures, including cultural validation of instruments if they provide information about the impact of interventions. The journal publishes study protocols and reviews summarising the present state of knowledge concerning a particular aspect of HRQOL and patient reported outcome measures. Reviews should generally follow systematic review methodology. Comments on articles and letters to the editor are welcome.